Drugs / Flucytosine
Flucytosine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANCOBON | — | 1971-11-26 | fda.gov ↗ |
Trials 29 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01985256 Background | Feb 2014 → Mar 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04194034 Background | Jan 2020 → Feb 2023 | colorectal neoplasm | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT06562621 Background | Aug 2018 → Aug 2022 | glioblastoma | Beijing Neurosurgical Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00012467 Background | Jan 2000 → Jul 2001 | Cryptococcal meningitis, HIV infectious disease | InterMune | Completed | No outcome recorded |
| Phase 2 | NCT00000776 Background | ? → Sep 1996 | Cryptococcal meningitis, HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06666322 Comparator | May 2025 → Apr 2032 expected | Cryptococcal meningitis, HIV infectious disease | University of Minnesota | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06178627 Comparator | Aug 2023 → Aug 2025 overdue | Cryptococcal meningitis | Huashan Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flucytosine | “2. Flucytosine 100mg/kg/day for 14 days in divided doses” NCT06666322 ↗25“ONF is an extended-release formulation of flucytosine.” NCT06562621 ↗ “flucytosine, 5-FC, 5-FC XR, Toca FC” NCT01470794 ↗ “Oral Flucytosine (5-FC)” NCT04226066 ↗ |
| Known as | 5-FC | “The combination of amphotericin and flucytosine (5-FC) has been the mainstay of therapy for the initial management of cryptococcal meningitis for 4 decades.” NCT06666322 ↗9“Combination of amphotericin and flucytosine (5-FC) is the mainstay of therapy for the initial management of CM.” NCT06414512 ↗ “Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy” NCT00583492 ↗ “Flucytosine (5-FC, Ancotil)” NCT03724071 ↗ “Flucytosine (5-FC)” NCT04194034 ↗ “Flucytosine (5-FC)” NCT01562626 ↗ “Flucytosine (5FC)” NCT06525389 ↗ “5-FC” NCT00978107 ↗ |
| Known as | 5-fluorocytosine | “To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal...” NCT00000639 ↗ |
| Known as | Alcobon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancoban | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancobon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancotil | “Flucytosine (5-FC, Ancotil)” NCT03724071 ↗ |
| Known as | DB107-FC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06264388 ↗ |
| Known as | FLC | “fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis” NCT00000708 ↗ |
| Known as | Flourocytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Flucitosina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | flucytosine, 5-FC, 5-FC XR, Toca FC | “flucytosine, 5-FC, 5-FC XR, Toca FC” NCT01470794 ↗ |
| Known as | Flucytosinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Fluorocytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | NSC-103805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | RO 2-9915 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Toca FC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576665 ↗ |
| Modality | Small molecule | — CHEMBL1463 ↗ |
| Route | Oral | “Non-AIDS patients assigned to AMB also take FLC by mouth daily.” NCT00000708 ↗ |